Loading
ZG006 is an experimental investigational agent whose form is not stated in the registry from Suzhou Zelgen Biopharmaceuticals in phase 3 trials for non-small-cell lung cancer and neuroendocrine tumours, with its target not yet stated publicly.
ZG006 is an investigational agent whose form is not stated in the registry developed by Suzhou Zelgen Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ZG006 will be administered as an intravenous (IV) infusion. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07189455 (Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer), in non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT07189455, plans to enrol 420 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.One arm of ZG006 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ZG006" OR ABSTRACT:"ZG006") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZG006, not a curated reading list.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours, Non-small-cell lung cancer and the tag pipeline.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.